EdiGene Company
![](/files/companies/default.png)
EdiGene is a clinical-stage biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer.
Headquarters:
China
Industry:
Stem Cell Exhaustion
Estimated Revenue:
$10M to $50M
Funding Status:
Early Stage Venture
Technology:
Rare Genetic Disorders
Founded Date:
2015